Search Results

(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company

👉 Ambition is the default setting of biotech. Platforms expand. Indications multiply. without compromising strategic control and biotech fundraising credibility? into sustainable progress and stronger biotech fundraising credibility. Why Ambition Naturally Expands in Biotech Companies 👉 Ambition in biotech is data-driven. In biotech, disciplined decisions today build strategic focus, execution clarity, and stronger biotech

👉 In early-stage biotech, activity often feels like strategy. At the same time, the team is preparing for biotech fundraising. in biotech is not complexity. In early-stage biotech, resources are finite. Capital is limited. How Strategic Overload Weakens Biotech Fundraising Signal 👉 Biotech fundraising is not only an evaluation

GPCR — Scaling Biotech Beyond the Bench Turning scientific excellence into scalable organizations. Leadership 👉 Ambition is the default setting of biotech. This is the hidden cost of ambition in biotech leadership. Not failure. Not poo Attila Foris Mar 2 The Real Cost of Strategic Overload in Biotech 👉 In early-stage biotech, At the same time, the team is preparing for biotech fundraising.

Transform your biotech idea or data into a clear, strategic roadmap with aligned biology, timelines, Home About Services News Get in Touch Welcome Biotech Growth Wherever You Are in Discovery—Let’s Build Biotech teams often tell me: “We have too many CROs and not enough clarity.” How I Help Biotechs Accelerate GPCR Discovery with Clarity, Speed & Confidence Decisions, Not More Data I work with early-stage biotechs—typically preclinical through IND-enabling—who need strategic clarity

When biotech partners trust your process, they come back again and again. Power My Discovery Biotech Clients Want Results - Not Confusion Every CRO I work with has great science—but Here's what I hear from biotech teams: “We’re not sure what we’re getting—or when we’re getting it.” How I Help CROs Deliver High-Impact Science That Biotech Teams Trust Biotech Clients Stay in Sync With What Matters We work together to position your CRO for growth • Refine your offering to match what biotech